GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

Shingrix [Herpes Zoster vaccine (recombinant, AS01 B ix adjuvanted)] is a non-live, recombinant subunit vaccine indicated for the prevention of shingles (herpes zoster) and, in some markets ...

Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of zoster vaccine for immunocompetent adults 60 years of age and older, based on the results of this study ...

Researchers conducted an observational study to compare the risk for dementia associated with both the live and recombinant shingles vaccines.

Derived from the Latin adjuvare (to help or aid), adjuvants enhance antigen-specific vaccine immunogenicity. Added only when ...

06, 2024 (GLOBE NEWSWIRE) -- The "Shingles Vaccine market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax), By Type (Recombinant Vaccine), By End-use (Private Healthcare ...

Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax), By Type (Recombinant Vaccine), By End-use (Private ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...